Skip to content

PREvention of bloodstream infections with Vancomycin resistant ENTerococci - Cohort Study

PREvention of bloodstream infections with Vancomycin resistant ENTerococci - Cohort Study - PREVENT (cohort study)

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
DRKS
Registry ID
DRKS00040222
Enrollment
248
Registered
2026-07-09
Start date
2026-08-03
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bloodstream infection by Vancomycin-resistant enterococci A49.13 U80.30

Interventions

Group 1: Patients with a bloodstream infection caused by vancomycin-resistant enterococci (VRE) are followed-up for 30 days regarding hospital mortality and the course of the bloodstream infection.

Sponsors

Universitätsklinikum Würzburg
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Blood culture-confirmed VRE-bloodstream infection

Exclusion criteria

Exclusion criteria: No clinical symptoms of bloodstream infection

Design outcomes

Primary

MeasureTime frame
Intrahospital mortality within 30 days after diagnosis. Data are collected via routine clinical documentation or, if necessary, through surveys (by telephone or mail) or inquiries to population registries.

Secondary

MeasureTime frame
Prolonged bloodstream infection (>72 hours). Time interval from admission to the onset of the bloodstream infection. Data are collected via routine clinical documentation at the time of diagnosis, 3–5 days after diagnosis, and 30 days after diagnosis.

Countries

Germany

Contacts

Public ContactKathrin Ungethüm

Universitätsklinikum Würzburg

prevent@ukw.de+49 931 201 47342

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Aug 10, 2026